Hepatitis B virus (HBV) causes an incurable and sometimes fatal liver disease striking several hundred thousand new victims every year all over the world. According to a recent World Health Organization estimate, approximately 2 billion of the 5.4 billion people of the world population have been infected with HBV.
Sci-B-Vac™ is a recombinant Hepatitis B vaccine, produced by Scigen Israel Ltd. It is produced in mammalian Chinese hamster ovary (CHO) cells, comprising the three HBV envelope proteins SHBs-S, MHBs-pre-S2, and LHBs-pre-S1. The Sci-B-Vac™ active component is highly similar to the wild type viral envelope, more potent and immunogenic than other existing yeast derived HB vaccines.